JDRF To Help Study Hypoglycemia
JDRF announces plans to participate in Hypo-RESOLVE research project.
The following is a press release provided by JDRF.
JDRF participates in new Research Project Hypo-RESOLVE to investigate Hypoglycaemia and its Impact in Diabetes –The international consortium aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes–
New York, May 1, 2018– Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes.
Diabetes is a global pandemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy. -Consisting of very low levels of blood glucose, hypoglycaemia can lead to cognitive decline, cardiovascular events and even death.
As much about hypoglycaemia remains unknown, the recently started European research project Hypo-RESOLVE (Hypoglycaemia – Redefining SOLutions for better liVEs) aims to provide researchers and clinicians with more validated data about the condition by:
· Creating a sustainable clinical database;
· Conducting studies to better understand the underlying mechanisms of hypoglycaemia;
· Conducting a series of statistical analyses to define predictors and consequences of hypoglycaemia;
· Calculating the financial cost in European countries.
“Our mission within Hypo-RESOLVE is to provide an evidence-based classification of hypoglycaemia based on secure data from 100 to 150 recently conducted clinical trials,” explained Dr Bastiaan de Galan, coordinator of Hypo-RESOLVE and internist at the department of Internal Medicine, Radboud university medical center, in the Netherlands. “With this statistical power, we will be able to make valid statements about the glucose thresholds below which hypoglycaemia constitutes a great risk for people living with diabetes.”
Dr Stephen Gough, Global Chief Medical Officer at Novo Nordisk in Denmark and Hypo-RESOLVE project leader added: “This consortium brings together world leaders from the field of diabetes to reduce the burden of hypoglycaemia. Hypo-RESOLVE paves the way for further research on glucose-lowering interventions that will serve people living with diabetes, clinicians and healthcare companies.”
“Hypoglycaemia remains the most pressing concern of all individuals living with diabetes, particularly insulin requiring diabetes such as type 1 diabetes,” explains Sanjoy Dutta, Ph.D., JDRF Assistant Vice President, Research & International Partnerships. “JDRF is pleased to be an active leader in this large public-private partnership to represent the voices of people affected with this condition, and to collectively understand the causes of and identify solutions to prevent hypoglycaemia.”
The voices of people living with diabetes will be at the heart of Hypo-RESOLVE, through the establishment of a Patient Advisory Committee. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.
“Hypoglycaemia presents a huge psychological burden for people with diabetes. We believe that the Patient Advisory Committee will help contribute to a better understanding of the disease’s impact on people with diabetes and ultimately help improve their lives,” said Prof. Nam H. Cho, President of the International Diabetes Federation (IDF). “Through this project, we also hope to strengthen public awareness of hypoglycaemia and diabetes generally.”
Hypo-RESOLVE is supported with funding of € 26.8 million from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust.
The project will officially kick off its activities with a first meeting in Denmark on May 16-17, 2018.
Project acronym: Hypo-RESOLVE
Start date: 01 May 2018
Duration: 48 months
Budget: € 26.8 Mio
Coordination: Radboud university medical center, Dr Bastiaan de Galan
Project Lead: Novo Nordisk A/S, Dr Stephen Gough
Project Management: Eurice – European Research and Project Office GmbH, Caroline Schorn
Hypo-RESOLVE Partners at a glance:
Medizinische Universität Graz
International Diabetes Federation
Nordsjællands University Hospital Hillerød
Novo Nordisk A/S
Centre Hospitalier Universitaire Montpellier
Eurice – European Research and Project Office GmbH (Project Management)
Sanofi-Aventis Deutschland GmbH
Universita Degli Studi di Padova
Radboud university medical center (RUMC) / Stichting Katholieke Universiteit (Coordination)
Medtronic International Trading Sarl
SIB Swiss Institute of Bioinformatics
Université de Lausanne
Eli Lilly and Company Limited
King’s College London
The Chancellor, Masters and Scholars of the University of Cambridge
The University of Edinburgh
The University of Sheffield
University of Dundee
The Leona M. and Harry B. Helmsley Charitable Trust
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF
Email : mediajdrf.org
Dr Bastiaan de Galan
Radboud university medical center / Stichting Katholieke Universiteit
Phone: +31 243618819
Dr Stephen Gough
Novo Nordisk A/S
Contact via Media Relations Lead Mette Kruse Danielsen
Phone: +45 30793883
International Diabetes Federation:
International Diabetes Federation
Phone: + 353 89 708 65 65
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation, and the Leona M. and Harry B. Helmsley Charitable Trust.
This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed.If you are not the named addressee, you are hereby notified that any review, dissemination, distribution or copying of this email is prohibited.Please notify the sender immediately by email if you have received this e-mail by mistake and delete this e-mail from your system.JDRF accepts no liability for the content of this e-mail, or for the consequences of any actions taken on the basis of the information provided, unless that information is subsequently confirmed in writing. Any views or opinions presented in this email are solely those of the author and do not necessarily represent those of the foundation unless otherwise stated and confirmed in writing in a form other than email. Although the company has taken reasonable precautions to ensure no viruses are present in this e-mail, the company accepts no liability for any damage caused by any virus transmitted by this e-mail or attachment(s).
JDRF, 26 Broadway 14th FL New York NY 10004 USA, www.jdrf.org